These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30654737)

  • 41. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of All Three Types in Cartilaginous Fishes Enables Phylogenetic Resolution of the Origins and Evolution of Interferons.
    Redmond AK; Zou J; Secombes CJ; Macqueen DJ; Dooley H
    Front Immunol; 2019; 10():1558. PubMed ID: 31354716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
    Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
    FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
    Halamkova J; Kiss I; Pavlovsky Z; Tomasek J; Jarkovsky J; Cech Z; Tucek S; Hanakova L; Moulis M; Zavrelova J; Man M; Benda P; Robek O; Kala Z; Penka M
    Neoplasma; 2011; 58(5):377-85. PubMed ID: 21744990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
    Boutaud A; Castellino FJ
    Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.
    Chu EK; Cheng J; Foley JS; Mecham BH; Owen CA; Haley KJ; Mariani TJ; Kohane IS; Tschumperlin DJ; Drazen JM
    Am J Respir Cell Mol Biol; 2006 Dec; 35(6):628-38. PubMed ID: 16794260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation and interactions in the activation of cell-associated plasminogen.
    Myöhänen H; Vaheri A
    Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library.
    Li CY; de Veer SJ; Law RHP; Whisstock JC; Craik DJ; Swedberg JE
    Chembiochem; 2019 Jan; 20(1):46-50. PubMed ID: 30225958
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
    Gershteĭn ES; Kushlinskiĭ NE
    Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasmin is not protective in experimental renal interstitial fibrosis.
    Edgtton KL; Gow RM; Kelly DJ; Carmeliet P; Kitching AR
    Kidney Int; 2004 Jul; 66(1):68-76. PubMed ID: 15200414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitors of the protease domain of urokinase-type plasminogen activator.
    Rockway TW; Nienaber V; Giranda VL
    Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes.
    García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M
    Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
    BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.